Replies to post #247 on Bottom Low Floaters

[MASTER P]

ADMD-near-term transformational catalyst-- as the firm works towards potential approval from the FDA on their 3 revolutionary products.
ADVANCED MEDICAL ISOTOPE CORPORATION – INNOVATION IN CANCER THERAPIES – WATCHING FOR FDA NEWS

Advanced Medical Isotope Corporation (OTCQB:ADMD) has filed applicatons for its Yttrium-90 (Y-90) RadioGel™ brachytherapy cancer treatment device, which utilizes a dissolvable (referred to as “resorbable”), biodegradable polymer and yttrium-90 microspheres for containment rather than metal or glass seeds. We believe odds of FDA clearance by mid-2015 are above 50%.
We believe the Company is on the verge of a major product introduction into the brachytherapy cancer treatment market. We view the Y-90 RadioGel™ device and the other Y-90 products as compelling hybrids between the legacy low dose rate products that utilize permanent seeds for the treatment of prostate cancer and the high dose rate therapies that are gaining in popularity.
There have been very few meaningful treatment developments for prostate cancer in quite some time. We believe the Company’s Y-90 isotope-based cancer therapy using a patented polymer delivery methodology could be one of the most significant advances in the treatment of prostate cancer within the past 10 years.
The safety profile of beta-emissions from the Y-90 isotope, for both patient and practitioner, is a significant improvement over currently available products with penetrating x-ray or gamma ray photons, because high-energy beta particles deliver a much higher percent of their radiation energy to the tumors being targeted, as contrasted to nearby healthy organs and tissues. Accordingly, we believe use of Y-90 also may provide superior efficacy, compared to legacy brachytherapy products.
The Y-90 RadioGel™ device and the other Y-90 products could begin generating substantial revenues at an attractive margin as early as late 2015.
The Company is also involved in the production of other isotopes used in nuclear medicine. Several of these critical isotopes are in short supply as available nuclear reactors are shutdown. This market offers an additional and steady potential revenue stream for the Company.
Over the coming weeks we will be watching for two events, news relative to FDA clearance and news relative to fundraising activities. Should we get positive news relative to either event, we would expect the shares to trade considerably higher.